News stories about Obalon Therptcs (NASDAQ:OBLN) have been trending somewhat negative this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Obalon Therptcs earned a coverage optimism score of -0.01 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.9940554752871 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

OBLN has been the topic of several analyst reports. Northland Securities initiated coverage on shares of Obalon Therptcs in a report on Wednesday, June 21st. They issued an “under perform” rating and a $6.00 target price on the stock. UBS AG reaffirmed a “buy” rating and issued a $20.00 target price (down previously from $22.00) on shares of Obalon Therptcs in a report on Thursday, August 3rd. Finally, Zacks Investment Research downgraded shares of Obalon Therptcs from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $15.17.

Shares of Obalon Therptcs (NASDAQ:OBLN) traded down 5.46% during mid-day trading on Friday, hitting $9.53. 31,813 shares of the stock traded hands. The firm’s 50 day moving average price is $9.78 and its 200-day moving average price is $9.78. The stock’s market cap is $160.33 million. Obalon Therptcs has a 12-month low of $8.27 and a 12-month high of $15.88.

Obalon Therptcs (NASDAQ:OBLN) last released its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.03). Obalon Therptcs had a negative return on equity of 108.07% and a negative net margin of 566.87%. The firm had revenue of $1.96 million during the quarter, compared to analyst estimates of $1.77 million. Analysts predict that Obalon Therptcs will post ($1.86) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Obalon Therptcs (OBLN) Given Daily Media Sentiment Score of -0.01” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/obalon-therptcs-obln-given-daily-media-sentiment-score-of-0-01/1601095.html.

Obalon Therptcs Company Profile

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

Insider Buying and Selling by Quarter for Obalon Therptcs (NASDAQ:OBLN)

Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with Analyst Ratings Network's FREE daily email newsletter.